News | PET Imaging | September 05, 2018

PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis

Flortaucipir F-18 demonstrates statistically significant sensitivity and specificity for brain changes

PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis

September 5, 2018 — Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET) imaging agent flortaucipir F-18 met its two primary endpoints, defined as predicting brain tau pathology and predicting Alzheimer's disease diagnosis.

The study, referred to as A16, enrolled a total of 156 end-of-life patients with dementia, mild cognitive impairment or normal cognition who underwent flortaucipir PET imaging. Subsequently, 67 of these patients were evaluated post-mortem. The study met pre-specified endpoints, with flortaucipir demonstrating statistically significant sensitivity and specificity for detecting tau pathology of Braak Stage V/VI, a pathological staging scale for tau neurofibrillary tangles. Flortaucipir also demonstrated statistically significant sensitivity and specificity for detecting a high level of total Alzheimer's disease neuropathologic change (combining both tau and amyloid plaque densities), using the National Institute on Aging and Alzheimer's Association (NIA-AA) neuropathology criteria.

Eli Lilly and Co. plans to disclose more detailed study results at the 2018 Clinical Trials on Alzheimer's Disease (CTAD) meeting, Oct. 24-27 in Barcelona, Spain, and will discuss these findings and potential next steps with the U.S. Food and Drug Administration (FDA) in the near future.

For more information: www.lilly.com

Related Content

Sponsored Content | Whitepapers | Clinical Trials | October 09, 2019
A 2019 N G PX REPORT
RSNA Announces Intracranial Hemorrhage AI Challenge
News | Artificial Intelligence | October 08, 2019
The Radiological Society of North America (RSNA) recently launched its third annual artificial intelligence (AI)...
AI Accurately Detects Key Chest X-Ray Pneumonia Findings Within 10 Seconds
News | Artificial Intelligence | September 30, 2019
Researchers from Intermountain Healthcare and Stanford University say 10 seconds is about how quickly a new system they...
AI Accurately Predicts Radiotherapy Side Effects for Head and Neck Cancer Patients
News | Artificial Intelligence | September 26, 2019
For the first time, a sophisticated computer model has been shown to accurately predict two of the most challenging...
Machine Learning Could Offer Faster, More Precise Cardiac MRI Scan Results
News | Magnetic Resonance Imaging (MRI) | September 25, 2019
Cardiac magnetic resonance imaging (MRI) analysis can be performed significantly faster with similar precision to...
Partial and Whole-Breast Radiotherapy After Lumpectomy Provide Equally Satisfying Cosmetic Results
News | Radiation Therapy | September 25, 2019
Whole breast radiation and partial breast radiation following a lumpectomy yield similar cosmetic outcomes for women...
Hippocampal Avoidance Using IMRT Now Recommended as Standard of Care for Brain Metastases
News | Radiation Therapy | September 24, 2019
Patients with brain metastases who received whole-brain radiotherapy that avoided memory-specific hippocampal neural...
High-dose Radiation Effective for Men Whose Prostate Cancer Has Spread
News | Prostate Cancer | September 23, 2019
A randomized clinical trial of targeted, high-dose radiation for men with oligometastatic prostate cancer has shown the...
An example of a treatment plan for radio-ablation of the heart to noninvasively treat cardiac arrhythmias. This concept is one of the key presentations at the 2019 ASTRO meeting. Image courtesy of Cyberheart. #ASTRO19 #ASTRO2019 #ASTRO

An example of a treatment plan for radio-ablation of the heart to noninvasively treat cardiac arrhythmias. This concept is one of the key presentations at the 2019 ASTRO meeting. Image courtesy of Cyberheart.

Feature | ASTRO | September 23, 2019
August 29, 2019 — The American Society for Radiation Oncology (ASTRO) announced th
Densitas Wins Major Procurement of Breast Density Software for DIMASOS Breast Screening Trial
News | Breast Density | September 20, 2019
Densitas Inc. announced it has won a procurement of its densitas densityai software for deployment in up to 24 breast...